Covid vax for S. Africa strain ready for human testing: Moderna

Covid vax for S. Africa strain ready for human testing: Moderna
New York, Feb 25 (Ians) US-based drugmaker Moderna said that it has completed manufacturing of clinical trial material for its variant-specific vaccine candidate against the Sars-CoV-2 variant known as B.1.351 -- first identified in the Republic of South Africa.

The company has shipped doses to the National Institutes of Health (Nih) for a Phase 1 clinical trial that will be led and funded by the Nih's National Institute of Allergy and Infectious Diseases (Niaid).

"As we seek to defeat Covid-19, we must be vigilant and proactive as new variants of Sars-CoV-2 emerge. Leveraging the flexibility of our mRNA platform, we are moving quickly to test updates to the vaccines that address emerging variants of the virus in the clinic," Stéphane Bancel, Chief Executive Officer of Moderna, said in a statement.

While initial data confirms that the Moderna Covid-19 vaccine (mRNA-1273) provides neutralizing activity against variants of concern, out of an abundance of caution,
See full article at GlamSham »

Similar News


Recently Viewed